GS vs LLY: Which Is the Better Buy?
Side-by-side comparison of The Goldman Sachs Group, Inc. and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
The Goldman Sachs Group, Inc. · Financial Services
$923.29
+25.9% upside to fair value
Med Conviction
Grade C
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
GS has more upside to fair value
(+25.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GS |
LLY |
| Current Price |
$923.29 |
$1,183.72 |
| Fair Value Estimate |
$1,162.79 |
$1,208.00 |
| Upside to Fair Value |
+25.9%
|
+2.1%
|
| Market Cap |
$272.4B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.3x
|
26.8x
|
| Price / Sales |
2.3x
|
14.0x
|
| Price / FCF |
—
|
52.7x
|
| Revenue Growth YoY |
+22.9%
|
+47.7%
|
| Gross Margin |
57.3%
|
83.4%
|
| Operating Margin |
24.8%
|
49.7%
|
| Return on Equity |
17.0%
|
92.6%
|
| Dividend Yield |
1.95% |
0.57% |
| FCF Yield |
—
|
1.9%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Goldman Sachs is a global financial services firm operating four divisions: Investment Banking, Global Markets, Asset Management, and Consumer & Wealth Management, with 46,200 full-time employees and a market cap of $272.38 billion at a current price of $923.29. The business quality is high because of its leading franchise in advisory, underwriting, and trading, evidenced by a 17.0% ROE, a 57.3% …
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
GS |
LLY |
| Zone Low |
$872.09 |
$906.00 |
| Zone High |
$988.37 |
$1,026.80 |
| In Buy Zone? |
Yes
|
No
|